Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.60 |
| ▸ | TERT | O14746 | 2/20 | 0.56 |
| ▸ | DTYMK | P23919 | 4/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.48 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21489391 | 1.00 | F2 (0.60) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL30639044 | 1.00 | F2 (0.60) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL29624021 | 1.00 | F2 (0.60) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL29362785 | 0.97 | TERT (0.57) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL21504636 | 0.97 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL21489387 | 0.97 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL29376007 | 0.97 | F2 (0.62) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL30369215 | 0.97 | F2 (0.62) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL29366358 | 0.97 | F2 (0.62) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL29624082 | 0.97 | F2 (0.62) | F2TERTDTYMKP2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025042729-A1 | CELL PREPARATION COMPOSITION, SYSTEM AND METHOD FOR SINGLE CELL TRANSCRIPTOMICS | Life Technologies Corporation (US) | 2025-02-27 | — | — | WO | disclosed |
| US-12043673-B2 | Complementary RNA linked bispecific T-cell engaging antibodies | CITY OF HOPE (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2023149775-A1 | OLIGONUCLEOTIDE FOR GENE DELIVERY AND LIPID NANOPARTICLE FOR GENE DELIVERY COMPRISING SAME | 한국과학기술원 | 2023-08-10 | — | — | WO | disclosed |
| US-20220119552-A1 | COMPLEMENTARY RNA LINKED BISPECIFIC T-CELL ENGAGING ANTIBODIES | CITY OF HOPE | 2022-04-21 | — | — | US | disclosed |
| US-11280758-B2 | Single-particle bridge assay for amplification-free electrical detection of ultralow-concentration biomolecules and non-biological molecules | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119552-A1 | COMPLEMENTARY RNA LINKED BISPECIFIC T-CELL ENGAGING ANTIBODIES | MCTS1, CD4, CD2 | F2 4607/4885TERT 772/4885DTYMK 79/4885 |
| US-12043673-B2 | Complementary RNA linked bispecific T-cell engaging antibodies | MCTS1, CD4, CD2 | F2 4607/4885TERT 772/4885DTYMK 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.